➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Dow
Medtronic
AstraZeneca
Moodys

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Patent: 6,706,289

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 6,706,289
Title: Methods and compositions for enhanced delivery of bioactive molecules
Abstract:Formulations for controlled, prolonged release of bioactive molecules such as therapeutic proteins, peptides and oligonucleotides have been developed. These formulations are based on solid microparticles or nanoparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof. Bioactive molecules are coupled to hydrophilic polymers such as polyethylene glycol or polypropylene glycol and formulated to provide controlled release. The bioactive molecules are more stable, less immunogenic and have improved release rate profiles with lower burst levels and increased drug loading relative to the same bioactive molecules lacking coupled hydrophilic polymers. The controlled release formulations can be administered by injection, by inhalation, nasally, or orally.
Inventor(s): Lewis; Danny (Hartselle, AL), Schmidt; Paul (Niwot, CO), Hinds; Kenneth (Fort Collins, CO)
Assignee: PR Pharmaceuticals, Inc. (Fort Collins, CO)
Application Number:09/999,820
Patent Claims:see list of patent claims

Details for Patent 6,706,289

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 1974-01-15 ⤷  Free Forever Trial 2020-10-31
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 1984-12-27 ⤷  Free Forever Trial 2020-10-31
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 1985-02-15 ⤷  Free Forever Trial 2020-10-31
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 1990-02-16 ⤷  Free Forever Trial 2020-10-31
Bel-mar Laboratories, Inc. CHORIONIC GONADOTROPIN chorionic gonadotropin Injection 017054 1974-03-26 ⤷  Free Forever Trial 2020-10-31
Fresenius Kabi Usa, Llc CHORIONIC GONADOTROPIN chorionic gonadotropin For Injection 017067 1973-03-05 ⤷  Free Forever Trial 2020-10-31
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 1978-01-10 ⤷  Free Forever Trial 2020-10-31
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Merck
Mallinckrodt
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.